HRP20201114T1 - Dugodjelujući polipeptidi i postupci njihove proizvodnje i primjene - Google Patents
Dugodjelujući polipeptidi i postupci njihove proizvodnje i primjene Download PDFInfo
- Publication number
- HRP20201114T1 HRP20201114T1 HRP20201114TT HRP20201114T HRP20201114T1 HR P20201114 T1 HRP20201114 T1 HR P20201114T1 HR P20201114T T HRP20201114T T HR P20201114TT HR P20201114 T HRP20201114 T HR P20201114T HR P20201114 T1 HRP20201114 T1 HR P20201114T1
- Authority
- HR
- Croatia
- Prior art keywords
- ctp
- modified polypeptide
- modified
- use according
- seq
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/059,134 US20140113860A1 (en) | 2006-02-03 | 2013-10-21 | Long-acting polypeptides and methods of producing and administering same |
| US14/309,496 US20150038413A1 (en) | 2006-02-03 | 2014-06-19 | Long-acting polypeptides and methods of producing and administering same |
| EP14856666.4A EP3060239B1 (en) | 2013-10-21 | 2014-10-21 | Long-acting polypeptides and methods of producing and administering same |
| PCT/IL2014/050910 WO2015059695A1 (en) | 2013-10-21 | 2014-10-21 | Long-acting polypeptides and methods of producing and administering same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201114T1 true HRP20201114T1 (hr) | 2020-10-30 |
Family
ID=52992360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201114TT HRP20201114T1 (hr) | 2013-10-21 | 2014-10-21 | Dugodjelujući polipeptidi i postupci njihove proizvodnje i primjene |
Country Status (21)
| Country | Link |
|---|---|
| EP (2) | EP3763733A1 (enExample) |
| JP (3) | JP6640720B2 (enExample) |
| KR (4) | KR20240110069A (enExample) |
| CN (1) | CN106163543A (enExample) |
| AU (3) | AU2014338575B2 (enExample) |
| CA (1) | CA2928269C (enExample) |
| DK (1) | DK3060239T3 (enExample) |
| ES (1) | ES2811068T3 (enExample) |
| FR (1) | FR22C1035I2 (enExample) |
| HR (1) | HRP20201114T1 (enExample) |
| HU (2) | HUE050002T2 (enExample) |
| IL (1) | IL297219B2 (enExample) |
| LU (1) | LUC00259I2 (enExample) |
| MX (2) | MX381148B (enExample) |
| NL (1) | NL301170I2 (enExample) |
| PL (1) | PL3060239T3 (enExample) |
| PT (1) | PT3060239T (enExample) |
| RU (1) | RU2746943C2 (enExample) |
| SI (1) | SI3060239T1 (enExample) |
| TW (5) | TWI893324B (enExample) |
| WO (1) | WO2015059695A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE050002T2 (hu) | 2013-10-21 | 2020-11-30 | Opko Biologics Ltd | Hosszan ható polipeptidek és eljárás azok elõállítására és beadására |
| CN118105512A (zh) * | 2016-08-30 | 2024-05-31 | 株式会社吉耐森 | 含有hGH融合蛋白的治疗生长激素缺乏症的药物组合物 |
| CN109942717A (zh) * | 2019-04-24 | 2019-06-28 | 上海延立药业有限公司 | 一种长效重组人促卵泡激素及其制备方法和应用 |
| US20240166710A1 (en) * | 2021-03-19 | 2024-05-23 | Pfizer Inc. | Methods of administering long-acting growth hormone polypeptides |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| DE3421468A1 (de) | 1984-06-08 | 1985-12-19 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| DE3751873T2 (de) | 1986-04-09 | 1997-02-13 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| EP0374257B1 (en) | 1988-05-06 | 1994-08-31 | Toray Industries, Inc. | STABLE INTERFERON $g(b) COMPOSITION |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| DE122010000006I2 (de) | 1989-02-21 | 2012-06-21 | Univ Washington | Modifizierte formen von fortpflanzungshormonen. |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
| US8476234B2 (en) * | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
| US8048849B2 (en) * | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US8304386B2 (en) * | 2006-02-03 | 2012-11-06 | Prolor Biotech, Inc. | Long-acting growth hormone and methods of producing same |
| US7553941B2 (en) * | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
| US8946155B2 (en) * | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8450269B2 (en) * | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| DE102007006189B4 (de) * | 2007-02-07 | 2009-07-30 | Isotopen Technologien München AG | Vorrichtung zum Befüllen eines medizinischen Instruments mit einer radioaktiven Substanz und Verfahren |
| HUE050002T2 (hu) | 2013-10-21 | 2020-11-30 | Opko Biologics Ltd | Hosszan ható polipeptidek és eljárás azok elõállítására és beadására |
-
2014
- 2014-10-21 HU HUE14856666A patent/HUE050002T2/hu unknown
- 2014-10-21 TW TW111132309A patent/TWI893324B/zh active
- 2014-10-21 HR HRP20201114TT patent/HRP20201114T1/hr unknown
- 2014-10-21 KR KR1020247021540A patent/KR20240110069A/ko not_active Ceased
- 2014-10-21 AU AU2014338575A patent/AU2014338575B2/en active Active
- 2014-10-21 EP EP20172836.7A patent/EP3763733A1/en active Pending
- 2014-10-21 PL PL14856666T patent/PL3060239T3/pl unknown
- 2014-10-21 JP JP2016525032A patent/JP6640720B2/ja active Active
- 2014-10-21 ES ES14856666T patent/ES2811068T3/es active Active
- 2014-10-21 CA CA2928269A patent/CA2928269C/en active Active
- 2014-10-21 KR KR1020167013555A patent/KR20160068969A/ko not_active Ceased
- 2014-10-21 EP EP14856666.4A patent/EP3060239B1/en active Active
- 2014-10-21 DK DK14856666.4T patent/DK3060239T3/da active
- 2014-10-21 CN CN201480070117.5A patent/CN106163543A/zh active Pending
- 2014-10-21 KR KR1020217030424A patent/KR102444140B1/ko active Active
- 2014-10-21 PT PT148566664T patent/PT3060239T/pt unknown
- 2014-10-21 RU RU2016119565A patent/RU2746943C2/ru active
- 2014-10-21 TW TW110104795A patent/TWI777407B/zh active
- 2014-10-21 MX MX2016005227A patent/MX381148B/es unknown
- 2014-10-21 TW TW103143380A patent/TWI720940B/zh active
- 2014-10-21 WO PCT/IL2014/050910 patent/WO2015059695A1/en not_active Ceased
- 2014-10-21 IL IL297219A patent/IL297219B2/en unknown
- 2014-10-21 TW TW103136384A patent/TWI720939B/zh active
- 2014-10-21 SI SI201431630T patent/SI3060239T1/sl unknown
- 2014-10-21 KR KR1020227031563A patent/KR20220130254A/ko not_active Ceased
- 2014-10-21 TW TW103143381A patent/TW201536312A/zh unknown
-
2016
- 2016-04-21 MX MX2021003908A patent/MX2021003908A/es unknown
-
2019
- 2019-12-26 JP JP2019236267A patent/JP7051797B2/ja active Active
-
2020
- 2020-02-06 AU AU2020200874A patent/AU2020200874A1/en not_active Abandoned
-
2022
- 2022-03-29 JP JP2022052919A patent/JP7445695B2/ja active Active
- 2022-04-19 NL NL301170C patent/NL301170I2/nl unknown
- 2022-05-02 HU HUS2200014C patent/HUS2200014I1/hu unknown
- 2022-05-06 LU LU00259C patent/LUC00259I2/fr unknown
- 2022-07-13 FR FR22C1035C patent/FR22C1035I2/fr active Active
- 2022-10-07 AU AU2022246472A patent/AU2022246472B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240635T1 (hr) | Dugodjelujući hormoni rasta i postupci proizvodnje istog | |
| ES2393233T3 (es) | Formulaciones de LH líquidas | |
| JP2014521684A5 (enExample) | ||
| ES2383796T3 (es) | Composiciones farmacéuticas que comprenden grelina no acilada para su utilización en el tratamiento de la resistencia a la insulina | |
| Johnson et al. | A month–long effect from a single injection of microencapsulated human growth hormone | |
| ES2202729T3 (es) | Hormona paratiroidea cristalina. | |
| JP2009525052A5 (enExample) | ||
| US20170360895A1 (en) | Long-acting insulin analogue preparations in insoluble and crystalline forms | |
| JP6101202B2 (ja) | ジペプチド結合医薬剤 | |
| US20150290328A1 (en) | Formulations of active agents for sustained release | |
| RU2015136440A (ru) | Композиции и способы применения для лечения метаболических расстройств | |
| JP2015507916A (ja) | グルタミン酸安定化インスリン類似体 | |
| RU2012153768A (ru) | Аналоги паратиреоидного гормона и их применение | |
| CN102711801A (zh) | 用顶压素样肽治疗心力衰竭的方法 | |
| MX2014008668A (es) | Formulacion de pth estabilizada. | |
| CN119173275A (zh) | Glp-1多肽的前药及其用途 | |
| ES2926627T3 (es) | Composición farmacéutica para tratar la deficiencia de hormona del crecimiento pediátrica que contiene proteína de fusión de hGH | |
| Cázares-Delgadillo et al. | Human growth hormone: new delivery systems, alternative routes of administration, and their pharmacological relevance | |
| ES2985989T3 (es) | Análogos de insulina novedosos y usos de estos | |
| JP2016535015A5 (enExample) | ||
| RU2016119565A (ru) | Полипептиды длительного действия и способы их получения и введения | |
| CN102272151A (zh) | Crhr2肽激动剂及其用途 | |
| CN104031141A (zh) | 用于治疗2型糖尿病的长效肠激素多肽类似物及应用 | |
| AU2013368990A1 (en) | Pharmaceutical composition | |
| US20100081622A1 (en) | Reduction of parathyroid hormone levels |